Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.
S Gupta, … , J Kim, S Gollapudi
S Gupta, … , J Kim, S Gollapudi
Published April 1, 1991
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
View: Text | PDF
Research Article Article has an altmetric score of 3

Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

  • Text
  • PDF
Abstract

Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.

Authors

S Gupta, J Kim, S Gollapudi

×

Total citations by year

Year: 2023 2022 2020 2017 2015 2014 2013 2010 2009 2007 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 Total
Citations: 1 2 1 3 2 1 2 1 1 1 1 1 2 2 1 2 3 3 2 1 3 1 2 1 40
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (40)

Title and authors Publication Year
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive
Kast RE
International journal of molecular sciences 2023
Induced Cell Cycle Arrest in Triple-Negative Breast Cancer by Combined Treatment of Itraconazole and Rapamycin.
Wu HT, Li CL, Fang ZX, Chen WJ, Lin WT, Liu J
Frontiers in pharmacology 2022
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer.
Lima TS, Souza LO, Iglesias-Gato D, Elversang J, Jørgensen FS, Kallunki T, Røder MA, Brasso K, Moreira JMA
Frontiers in pharmacology 2022
Repurposing old drugs to fight multidrug resistant cancers
J Dinić, T Efferth, AT García-Sosa, J Grahovac, JM Padrón, I Pajeva, F Rizzolio, S Saponara, G Spengler, I Tsakovska
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2020
Repurposing itraconazole as an anticancer agent
H Tsubamoto, T Ueda, K Inoue, K Sakata, H Shibahara, T Sonoda
Oncology Letters 2017
Repurposing itraconazole for the treatment of cancer
R Pounds, S Leonard, C Dawson, S Kehoe
Oncology Letters 2017
Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation
HM Treshalina, VI Romanenko, DN Kaluzhny, MI Treshalin, AA Nikitin, AS Tikhomirov, AE Shchekotikhin
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2017
Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells
C Stäubert, R Krakowsky, H Bhuiyan, B Witek, A Lindahl, O Broom, A Nordström
Medical Oncology 2015
Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
P Pantziarka
ecancermedicalscience 2015
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
RE Kast, G Karpel-Massler, ME Halatsch
Oncotarget 2014
Pharmacokinetic and Pharmacodynamic Interaction of Nadolol With Itraconazole, Rifampicin and Grapefruit Juice in Healthy Volunteers: The Journal of Clinical Pharmacology
S Misaka, N Miyazaki, MS Yatabe, T Ono, Y Shikama, T Fukushima, J Kimura
The Journal of Clinical Pharmacology 2013
Effects of Itraconazole, Dexamethasone and Naringin on Pharmacokinetics of Nadolol in Rats
N Miyazaki, S Misaka, H Ogata, T Fukushima, J Kimura
Drug Metabolism and Pharmacokinetics 2013
Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4
T Yoshikado, T Takada, T Yamamoto, H Yamaji, K Ito, T Santa, H Yokota, Y Yatomi, H Yoshida, J Goto, S Tsuji, H Suzuki
Molecular pharmacology 2010
Cytochrome P450-mediated metabolism in the human gut wall
K Thelen, JB Dressman
Journal of Pharmacy and Pharmacology 2009
Side Effects of Drugs Annual
T Vial, J Descotes, F Braun, M Behrend
Side Effects of Drugs Annual 2007
Effect of Itraconazole on the Pharmacokinetics of Atenolol
JJ Lilja, JT Backman, PJ Neuvonen
Basic & Clinical Pharmacology & Toxicology 2005
Renal Interaction Between Itraconazole and Cimetidine
CS Karyekar, ND Eddington, A Briglia, PO Gubbins, TC Dowling
The Journal of Clinical Pharmacology 2004
Evaluation of P-glycoprotein–Mediated Renal Drug Interactions in an MDR1-MDCK Model
CS Karyekar, ND Eddington, TS Garimella, PO Gubbins, TC Dowling
Pharmacotherapy 2003
Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [ 14 C]erythromycin breath and urine test
WP Lemahieu, BD Maes, Y Ghoos, P Rutgeerts, K Verbeke, Y Vanrenterghem
AJP Gastrointestinal and Liver Physiology 2003
Detection of Human P-Glycoprotein-like Molecule in Azole-ResistantCandida albicansfrom HIV+Patients
A Stringaro, A Molinari, A Calcabrini, G Arancia, PG Ceddia, M Cianfriglia, F Poloni, F Mondello, L Angiolella, FD Bernardis, A Cassone
Microbial Drug Resistance 2002
Interaction of common azole antifungals with P glycoprotein
E Wang, K Lew, CN Casciano, RP Clement, WW Johnson
Antimicrobial agents and chemotherapy 2002
Reversal Effects of Antifungal Drugs on Multidrug Resistance in MDR1-Overexpressing HeLa Cells
N IIDA, K TAKARA, N OHMOTO, T NAKAMURA, T KIMURA, A WADA, M HIRAI, T SAKAEDA, K OKUMURA
Biological & Pharmaceutical Bulletin 2001
Effects of the Antifungal Agents on Oxidative Drug Metabolism
K Venkatakrishnan, LL von Moltke, DJ Greenblatt
Clinical Pharmacokinetics 2000
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
K Venkatakrishnan, LL von Moltke, DJ Greenblatt
Clinical Pharmacokinetics 2000
Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs
K Nishihara, J Hibino, H Kotaki, Y Sawada, T Iga
Biopharmaceutics & Drug Disposition 1999
The Contribution of P-glycoprotein to Pharmacokinetic Drug-Drug Interactions
DK Yu
The Journal of Clinical Pharmacology 1999
Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells
S Ito, C Woodland, B Sarkadi, G Hockmann, SE Walker, G Koren
American journal of physiology. Renal physiology 1999
Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients
U Christians, W Jacobsen, LC Floren
Pharmacology & Therapeutics 1998
Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein*
H Wakasugi, I Yano, T Ito, T Hashida, T Futami, R Nohara, S Sasayama, K Inui
Clinical Pharmacology & Therapeutics 1998
P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier
T Miyama, H Takanaga, H Matsuo, K Yamano, K Yamamoto, T Iga, M Naito, T Tsuruo, H Ishizuka, Y Kawahara, Y Sawada
Antimicrobial agents and chemotherapy 1998
Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs
A Cavalier, D Levêque, JD Peter, J Salmon, H Elkhaïli, Y Salmon, P Nobelis, J Geisert, H Monteil, F Jehl
Antimicrobial agents and chemotherapy 1997
Comment: Possible Mechanism of Digoxin–Itraconazole Interaction
S Ito, G Koren, CP Alderman, P Allcroft
The Annals of pharmacotherapy 1997
Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells
M Kurosawa, M Okabe, N Hara, K Kawamura, S Suzuki, K Sakurada, M Asaka
Annals of Hematology 1996
Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL
A Böhme, A Ganser, D Hoelzer
Annals of Hematology 1995
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
VJ Wacher, CY Wu, LZ Benet
Molecular Carcinogenesis 1995
Itraconazole and retinoid resistance
H Ueno, M Kizaki, N Takayama, H Matsushita, A Muto, S Okamoto, Y Ikeda
American Journal of Hematology 1995
Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances
H Wiseman
Trends in Pharmacological Sciences 1994
Itraconazole and multidrug resistance: Possible effects on remission rate and disease-free survival in acute leukemia
G Vreugdenhil, JM Raemaekers, BJ Dijke, BE Pauw
Annals of Hematology 1993
Itraconazole and multidrug resistance: Possible effects on remission rate and disease-free survival in acute leukemia
G Vreugdenhil, JM Raemaekers, BJ van Dijke, BE de Pauw
Annals of Hematology 1993
Abnormal chloride conductance in multidrug resistant HL60AR cells
S Gollapudi, T McDonald, P Gardner, N Kang, S Gupta
Cancer Letters 1992

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 4 patents
11 readers on Mendeley
See more details